Stocks and Investing
Stocks and Investing
Fri, October 15, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, October 14, 2021
Jeffrey Hung Downgraded (ACAD) to Hold and Held Target at $20 on, Oct 14th, 2021
Jeffrey Hung of Morgan Stanley, Downgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Hold and Held Target at $20 on, Oct 14th, 2021.
Jeffrey has made no other calls on ACAD in the last 4 months.
There are 3 other peers that have a rating on ACAD. Out of the 3 peers that are also analyzing ACAD, 1 agrees with Jeffrey's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $25 on, Thursday, August 5th, 2021
These are the ratings of the 2 analyists that currently disagree with Jeffrey
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $26 on, Thursday, August 5th, 2021
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $28 on, Thursday, August 5th, 2021
Contributing Sources